title: Disruption of coordinated cardiac hypertrophy and angiogenesis contributes to the transition to heart failure.
abstract: Although increased external load initially induces cardiac hypertrophy with preserved contractility, sustained overload eventually leads to heart failure through poorly understood mechanisms. Here we describe a conditional transgenic system in mice characterized by the sequential development of adaptive cardiac hypertrophy with preserved contractility in the acute phase and dilated cardiomyopathy in the chronic phase following the induction of an activated Akt1 gene in the heart. Coronary angiogenesis was enhanced during the acute phase of adaptive cardiac growth but reduced as hearts underwent pathological remodeling. Enhanced angiogenesis in the acute phase was associated with mammalian target of rapamycin-dependent induction of myocardial VEGF and angiopoietin-2 expression. Inhibition of angiogenesis by a decoy VEGF receptor in the acute phase led to decreased capillary density, contractile dysfunction, and impaired cardiac growth. Thus, both heart size and cardiac function are angiogenesis dependent, and disruption of coordinated tissue growth and angiogenesis in the heart contributes to the progression from adaptive cardiac hypertrophy to heart failure.
authors.affiliation: Molecular Cardiology, Whitaker Cardiovascular Institute, Boston University School of Medicine, Boston, Massachusetts 02118, USA.
authors.forename: Ichiro
authors.initials: I
authors.lastname: Shiojima
authors.forename: Kaori
authors.initials: K
authors.lastname: Sato
authors.forename: Yasuhiro
authors.initials: Y
authors.lastname: Izumiya
authors.forename: Stephan
authors.initials: S
authors.lastname: Schiekofer
authors.forename: Masahiro
authors.initials: M
authors.lastname: Ito
authors.forename: Ronglih
authors.initials: R
authors.lastname: Liao
authors.forename: Wilson S
authors.initials: WS
authors.lastname: Colucci
authors.forename: Kenneth
authors.initials: K
authors.lastname: Walsh
mesh_terms: D042702:Angiopoietin-2 / Q000096:biosynthesis; D000818:Animals; D002311:Cardiomyopathy, Dilated / Q000201:enzymology* / Q000235:genetics / Q000473:pathology; D005786:Gene Expression Regulation / Q000235:genetics; D006321:Heart / Q000254:growth & development; D006333:Heart Failure / Q000201:enzymology* / Q000235:genetics / Q000473:pathology; D006801:Humans; D051379:Mice; D008822:Mice, Transgenic; D009206:Myocardium / Q000201:enzymology* / Q000473:pathology; D009389:Neovascularization, Pathologic / Q000201:enzymology* / Q000235:genetics; D017346:Protein Serine-Threonine Kinases / Q000235:genetics / Q000378:metabolism*; D011518:Proto-Oncogene Proteins / Q000235:genetics / Q000378:metabolism*; D051057:Proto-Oncogene Proteins c-akt; D042461:Vascular Endothelial Growth Factor A / Q000096:biosynthesis; D020257:Ventricular Remodeling / Q000235:genetics
chemical_list: D042702:Angiopoietin-2; D011518:Proto-Oncogene Proteins; D042461:Vascular Endothelial Growth Factor A; C494918:AKT1 protein, human; D017346:Protein Serine-Threonine Kinases; D051057:Proto-Oncogene Proteins c-akt